iPSC Platform

The development of high-quality cell models derived from human induced pluripotent stem cells (iPSCs), offers many advantages over recombinant cell lines, avoiding issues related to non-physiological overexpression of the target and allowing the use of relevant cellular disease models.

Axxam's iPSC Unit has a vast experience in the manipulation of these delicate cells and through collaborations with established partners, we can support you in the development of robust and pathophysiologically relevant assays.

iPSC-Derived Cellular Models

Neurons (Gluta; DOPA; Motor, Sensory)

Genome editing with CRISPR/Cas9

- Cardiomyocytes
- **Myotubes**
- Hepatocytes
- Macrophages
- Microglia
- Partnership with

Innovative Tools

Assay Development

Aggregation assays

Calcium oscillation

Cytokine release


Neurite outgrowth


Cytotoxicity


Gene expression analysis

Optogenetics











Applicability

Screening campaign Compound profiling and hit-to-lead Target identification / validation

Readouts

Optical detection Electrophysiology Gene expression Phenotypic - High content analyses







AXXAM S.p.A. Corporate Offices & Laboratories OpenZone - Via Meucci 3, 20091 Bresso (Milan), Italy

info@axxam.com www.axxam.com